Intelligence · Patents
Patents expiring in 2041
Annual patent cliff calendar for 2041 — US pharmaceutical patents by expiration date.
- Patents
- 2,000
Quick answer
2,000 indexed pharmaceutical patents have expiration dates in 2041. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 10947509
Cell populations, methods of transdifferentiation and methods of use thereof
granted -
US 10946065
Methods of treating fungal infections
granted -
US 10946107
Polynucleotide agents targeting hydroxyacid oxidase (glycolate oxidase, HAO1) and methods of use thereof
granted -
US 10947254
Methods for treating ulcerative colitis using 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile
granted -
US 10945993
Methods of recruiting SDF-producing macrophages
granted -
US 10947310
Fusion protein comprising apelin and an anti-APLNR antibody
granted -
US 10946009
Combination dosage form of a mu opioid receptor antagonist and an opioid agent
granted -
US 10947505
Methods and compositions for inducing hematopoietic cell differentiation
granted -
US 10947312
Human antibodies to GFRα3 and methods of making thereof
granted -
US 10945972
Particulate materials
granted -
US 10946106
Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen
granted -
US 10946033
2′-substituted-N6-substituted purine nucleotides for RNA virus treatment
granted -
US 10946044
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
granted -
US 10946308
Enzymatic method for extraction and purification of phytocannabinoids
granted -
US 10947302
Compositions targeting 3-repeat tau for the treatment of neurodegenerative disorders, and methods for making and using them
granted -
US 10947277
Nucleic acids encoding zika virus-like particles and their use in zika virus vaccines and diagnostic assays
granted -
US 10947238
Wee1 kinase inhibitors and methods of making and using the same
granted -
US 10947198
Chroman-substituted, tetrahydroquinoline-substituted and thiochroman-substituted heteroarotinoids as anti-cancer agents
granted -
US 10945503
Systems, devices and methods for styling hair
granted -
US 10946047
Extracellular vesicles with enhanced potency
granted -
US 10945964
Microencapsulated chitosan, methods of making and methods for the use thereof
granted -
US 10946080
Compositions and methods for combination therapy with dengue virus and dendritic cells
granted -
US 10945962
Controlled-release peptide compositions and uses thereof
granted -
US 10947180
Phenoxy acetic acids and phenyl propionic acids as PPAR delta agonists
granted -
US 10947507
Platform for generating safe cell therapeutics
granted -
EP 3791896
KOMBINATIONSTHERAPIE MIT ANTIKÖRPERN GEGEN CLAUDIN 18.2 ZUR BEHANDLUNG VON KREBS
granted -
WO 2021048135
COMBINAISONS PHARMACEUTIQUES COMPRENANT UN FURAZANOBENZIMIDAZOLE ET UN AGONISTE DE CD40 POUR UNE UTILISATION DANS LE TRAITEMENT DE MALADIES NÉOPLASIQUES
granted -
US 10953110
Dual emissive metal nanoparticles as ratiometric pH indicators
granted -
US 10954192
Pyrrolomycins and methods of using the same
granted -
US 10952993
Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
granted -
US 10952970
Use of vitelline protein B as a microencapsulating additive
granted -
US 10952980
GABA agonists in the treatment of disorders associated with metabolic syndrome and GABA combinations in treatment or prophylaxis of type I diabetes
granted -
US 10953028
Method of treating heterotopic ossification
granted -
US 10953085
Genetically engineered Foot and Mouth Disease Virus and related proteins, polynucleotides, compositions, methods and systems
granted -
US 10952997
Methods for the administration of certain VMAT2 inhibitors
granted -
US 10953187
Configurable oxygen concentrator and related method
granted -
US 10953000
Combination of pimavanserin and cytochrome P450 modulators
granted -
US 10953018
Emulsion formulations of aprepitant
granted -
US 10953003
Methods for treating cancer
granted -
US 10954291
Monoclonal antibodies that specifically bind to matrilin-3 and their use
granted -
US 10954294
Correctly folded etanercept in high purity and excellent yield
granted -
US 10953031
Compounds and methods for treating neurological and cardiovascular conditions
granted -
US 10953046
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
granted -
US 10953098
Chemical structures for localized delivery of therapeutic agents
granted -
US 10954268
Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers
granted -
US 10954228
1 H-pyrazol-1-yl-thiazoles as inhibitors of lactate dehydrogenase and methods of use thereof
granted -
US 10954237
JAK inhibitors containing a 4-membered heterocyclic amide
granted -
US 10953077
Method of delivering a somatostatin compound into a lumen of the intestinal tract using a swallowable drug delivery device
granted
Frequently asked questions
How many pharma patents expire in 2041?
2,000 published patents in our USPTO index have expiration dates falling in calendar year 2041.